Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Adjuvant doxorubicin and ifosfamide boost outcomes in soft tissue sarcomas

Pasquali S et al. ASCO 2018, Abstract 115118.

Key clinical point: Patients with high-risk soft-tissue sarcomas benefit from adjuvant chemotherapy.

Major finding: Hazard ratios for death and disease progression in patients with a low probability of 10-year overall survival were 0.46 for each.

Study details: Retrospective analysis of a randomized phase 3 trial comparing adjuvant chemotherapy with observation in 290 patients with soft tissue sarcomas of the trunk wall or extremities.

Disclosures: The study was supported by the European Organisation for Research and Treatment of Cancer. Dr. Pasquali reported having no conflicts of interest.

Source: Pasquali S et al. ASCO 2018, Abstract 115118.

Read the article.

Citation:

Pasquali S et al. ASCO 2018, Abstract 115118.

This Week's Must Reads

Case studies shed light on treatment for rare form of MCL , Mori S et al. Clin Lymphoma Myeloma Leuk. 2019 Feb;19(2):e93-7.

Histopathological clues for differentiating follicular lymphomas, Servitje O et al. J Cutan Pathol. 2019;46:182-9.

Single agent daratumumab is not an option in B-cell lymphomas, Salles G et al. Clin Lymphoma Myeloma Leuk. 2019 Jan 2. doi: 10.1016/j.clml.2018.12.013.

Ibrutinib combo advances in CNS lymphoma, Grommes C et al. Blood. 2019;133(5):436-45.

Best frontline options for advanced follicular lymphoma, Shah NN et al. Clin Lymphoma Myeloma Leuk. 2019 Feb;19(2):95-102.

Must Reads in Sarcoma & GIST

Intensity modulated radiation therapy may be preferable in children with extremity nonrhabdomyosarcoma soft-tissue sarcomas, Source: Rao A et al. Intl J Rad Oncology*Biology*Physics; Jan. 2019, 38-44. https://doi.org/10.1016/j.ijrobp.2018.09.005

Expanded genetic analyses of myxofibrosarcomas may guide precision therapies, Ogura K et al. Nature Communications; 17 July 2018. https://doi.org/10.1038/s41467-018-03891-9

Malignant tenosynovial giant cell tumors appear to originate from synoviocytes, Al-Ibraheemi A et al. Modern Pathology; 11 Sept. 2018. https://doi.org/10.1038/s41379-018-0129-0

Type and rate of clonal evolution vary widely in sarcoma pathogenetic subgroups, Hofvander J et al. Nature Communications 10 Sept. 2018. https://doi.org/10.1038/s41467-018-06098-0

Increasing pannexin 1 levels might be a novel treatment for rhabdomyosarcoma , Xiang X et al. Oncogenesis; 21 Nov. 2018. https://doi.org/10.1038/s41389-018-0100-4